NDA 209521 · Almirall
Seysara
Sarecycline Hydrochloride · Oral
NovelLast checked: Nov 20, 2026Latest source record: Mar 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Oct 1, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
8
3 Phase 3, 1 recruiting
FAERS reports
200
39 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 5, 2024.
SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections [see Clinical Studies ( 14 )] . To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )] . SEYSARA ® is a tetracycline-class drug indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. ( 1 ) Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )].
Mechanism: Sarecycline is an aminomethylcycline within the tetracycline class of drugs. [see CLINICAL PHARMACOLOGY ( 12.4 )] . The mechanism of action of SEYSARA in treating the inflammatory lesions of non-nodular acne vulgaris is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
- SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription
- SEYSARA · SARECYCLINE HYDROCHLORIDE EQ 60MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sarecycline" as an intervention, any sponsor and status, largest first.
- Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of AcnePivotal-lookingCompleted
Almirall, S.A.Industry
NCT02322866 · 1,034 participants · Start Dec 3, 2014 · Primary completion Jan 12, 2017
Drug: Sarecycline; Placebo · For: Acne Vulgaris
Sites: Mobile, Alabama; Hot Springs, Arkansas; Carlsbad, California · 57 sites in all
- Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of AcnePivotal-lookingCompleted
Almirall, S.A.Industry
NCT02320149 · 968 participants · Start Dec 18, 2014 · Primary completion Feb 1, 2017
Drug: Sarecycline; Placebo · For: Acne Vulgaris
Sites: Beverly Hills, California; Encino, California; La Mesa, California · 57 sites in all
- A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne VulgarisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT02413346 · 490 participants · Start Mar 20, 2015 · Primary completion Aug 26, 2016
Drug: Sarecycline · For: Acne Vulgaris
Sites: Mobile, Alabama; Hot Springs, Arkansas; Carlsbad, California · 56 sites in all
- Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of a Novel Tetracycline in the Treatment of Facial Acne VulgarisPivotal-lookingCompleted
Almirall, S.A.Industry
NCT01628549 · 285 participants · Start Jun 30, 2012 · Primary completion Nov 16, 2012
Drug: 50 mg P005672-HCl; Placebo and 1 more · For: Acne Vulgaris
Sites: Mobile, Alabama; Tucson, Arizona; Hot Springs, Arkansas · 38 sites in all
- Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion TherapyPivotal-lookingStatus unknown
Beijing Tiantan HospitalAcademic, hospital or other
NCT05836753 · 120 participants (planned) · Start May 7, 2023 · Primary completion Nov 2023
Drug: Sarecycline Tablet; Placebo tablets of Sarecycline tablets · For: Ischemic Stroke, Acute
Sites: Beijing, China
- A Pilot Study on the Use of Seysara for RosaceaPivotal-lookingCompleted
Derm Research, PLLCAcademic, hospital or other
NCT04555525 · 100 participants · Start Apr 15, 2019 · Primary completion Sep 23, 2020
Drug: sarecycline · For: Acne Rosacea
Sites: Louisville, Kentucky
Integrative Skin Science and ResearchIndustry
NCT07544251 · 30 participants (planned) · Start Apr 20, 2026 · Primary completion Apr 2027
Drug: Sarecycline; Doxycycline · For: Acne Vulgaris
Sites: Sacramento, California
The Dermatology Institute of BostonAcademic, hospital or other
NCT06461299 · 9 participants · Start Jul 17, 2023 · Primary completion Mar 31, 2024
Drug: Seysara Oral Product · For: Perioral Dermatitis
Sites: Boston, Massachusetts
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache24
- drug ineffective14
- dizziness13
- vision blurred11
- rash9
- off label use8
- product dose omission issue8
- pruritus8
- condition aggravated7
- fatigue7
- nausea7
- anxiety6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 35 |
| 2020 | 27 |
| 2021 | 24 |
| 2022 | 21 |
| 2023 | 23 |
| 2024 | 30 |
| 2025 | 12 |
| 2026 | 28 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Seysara (Sarecycline HCl)
2024 spending
$786K
Beneficiaries
200
637 claims
Per beneficiary
$3,929
$33.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $163,508 |
| 2021 | $417,016 |
| 2022 | $535,840 |
| 2023 | $657,586 |
| 2024 | $785,827 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Guidelines of care for the management of acne vulgaris.
Reynolds RV, Yeung H, Cheng CE, et al. · J Am Acad Dermatol 2024 · Practice Guideline, Systematic Review
- Sarecycline Review.
Haidari W, Bruinsma R, Cardenas-de la Garza JA, et al. · Ann Pharmacother 2020 · Systematic Review
- Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug.
Elrosasy A, Abo Zeid M, AlEdani EM, et al. · Naunyn Schmiedebergs Arch Pharmacol 2025 · Meta-Analysis, Systematic Review
- Oral Tetracyclines and Acne: A Systematic Review for Dermatologists.
Armstrong AW, Hekmatjah J, Kircik LH · J Drugs Dermatol 2020 · Systematic Review
- Management of Truncal Acne With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials.
Del Rosso JQ, Stein Gold L, Baldwin H, et al. · J Drugs Dermatol 2021 · Clinical Trial, Phase III
- Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study.
Leyden JJ, Sniukiene V, Berk DR, et al. · J Drugs Dermatol 2018 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Almirall
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.